Janssen Pharmaceuticals is advising caution in Japan following the deaths of 17 patients who were given injections of its schizophrenia drug. The Japanese unit of major drug maker Janssen ...

Elan Drug Technologies (EDT), the drug delivery unit of Elan Corporation, plc (NYSE: ELN), today announced that the first injectable product using EDT's NanoCrystal® technology has been approved by ...

Janssen announced the launch of Xeplion (paliperidone palmitate), a new once-monthly, Long-Acting Injectable (LAI) anti-psychotic available in the UK. Paliperidone palmitate provides sustained and ...

Janssen-Cilag International NV announced that Xeplion (paliperidone palmitate), a once monthly, long-acting injectable, antipsychotic, has received approval from the European Commission for the ...

BEERSE, Belgium, March 9, 2011 /PRNewswire/ -- Janssen-Cilag International NV today announced that XEPLION(R) (paliperidone palmitate), a once monthly, long-acting injectable, antipsychotic, has ...

Tokyo: The Japanese unit of major drugmaker Janssen Pharmaceuticals says 17 people have died after being injected with its drug to treat schizophrenia since it was launched in Japan last November. The ...

If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...

Janssen’s three-monthly injection for schizophrenia, Trevicta (paliperidone palmitate), has been approved in Europe, providing the longest dosing interval for an antipsychotic medicine in the EU. The ...